¼¼°èÀÇ Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : Á¦Ç°º°, ±â¼úº°, ¾à¹°±ºº°, Ä¡·á ºÐ¾ßº°, °Ëüº°, ÃÖÁ¾»ç¿ëÀÚº° - ¿¹Ãø(-2029³â)
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs,Anti-Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
»óǰÄÚµå : 1620872
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,621,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,792,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå ±Ô¸ð´Â 2024³â 23¾ï ´Þ·¯¿¡¼­ 2029³â±îÁö 34¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 8.4%ÀÇ °ÇÀüÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸é¿ªºÐ¼® ±â¼úÀÇ ¹ßÀüÀº ¿©ÀüÈ÷ ÀÌ ¼ºÀåÀÇ ÁÖ¿ä ÃËÁøÁ¦À̸ç, ÀÌ ºÎ¹®ÀÇ ±Ëµµ¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº °­È­ È­Çй߱¤, ELISA, Çü±¤Áõ°­ µî ¾à¹° ¸ð´ÏÅ͸µÀÇ Á¤È®¼º, ¼Óµµ ¹× ƯÀ̼ºÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÇÑÆí, ÀÇ·áÁøÀº TDMÀÌ Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÀÖ¾î TDMÀÇ Á߿伺À» ´õ Àß ÀνÄÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÓ»ó ÇöÀå¿¡ TDMÀ» µµÀÔÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±³À° ¹× Æ®·¹ÀÌ´×À» ÅëÇØ ÀÓ»óÀǵéÀÌ TDMÀÇ ÀÌÁ¡À» ´õ Àß ÀÌÇØÇϰí ÀÏ»ó Áø·á¿¡ ½±°Ô µµÀÔÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÌ ÃÑüÀûÀ¸·Î ¿ªµ¿ÀûÀ¸·Î ¼ºÀåÇÏ´Â ½ÃÀå ȯ°æ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2022-2029³â
±âÁØ ¿¬µµ 2023³â
¿¹Ãø ±â°£ 2024-2029³â
´ÜÀ§ ´Þ·¯
ºÎ¹® Á¦Ç°, ±â¼ú, ¾à¹°±º, Ä¡·á ¿µ¿ª, °Ëü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, GCC ±¹°¡

"Á¦Ç°º°·Î´Â ¼Ò¸ðǰ ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù."

Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM)¿¡¼­ ¼Ò¸ðǰ ºÎ¹®Àº °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Ã¾à, ¾î¼¼ÀÌ Å°Æ®, ͏®ºê·¹ÀÌÅÍ¿Í °°Àº ¼Ò¸ðǰÀº ¾Ï, ½ÉÇ÷°üÁúȯ, ½Å°æ Áúȯ°ú °°ÀÌ ¸¸¼ºÀûÀ̰í Ä¡·á°¡ º¹ÀâÇÑ ÁúȯÀÇ Ä¡·áÁ¦¸¦ ÀÏ»óÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â µ¥ ÇʼöÀûÀ̱⠶§¹®¿¡ TDM ½ÃÀå¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í Á¤È®ÇÑ ¾à¹° ¼öÁØ Æò°¡¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °íǰÁú ¼Ò¸ðǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸¼Ò¿Í º´¿øÀÌ Ã·´Ü TDM ½Ã½ºÅÛ¿¡ ÅõÀÚÇÏ´Â ÀÚ±ÝÀº °ü·Ã Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ½ÃÀå È®ÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

"Ç¥º»º°·Î´Â Ç÷¾× ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù."

Ç÷¾×Àº TDM¿¡ °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ½Ã·á·Î, Ç÷Àå ¹× Ç÷û ³» ¾à¹° ³óµµ¸¦ Á¤È®Çϰí Á÷Á¢ÀûÀ¸·Î ÃøÁ¤ÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Ç÷¾×ÀÇ Ã¤Ãë¿Í 󸮿¡ ´ëÇÑ È®¸³µÈ ÇÁ·ÎÅäÄÝÀÌ ÀÖ¾î ½Å·Ú¼º°ú Àϰü¼ºÀÌ º¸ÀåµË´Ï´Ù. ¶ÇÇÑ, ¸é¿ªºÐ¼®, LC-MS/MS µî ÃÖ÷´Ü ±â¼ú°ú ȣȯµÇ¾î ¾à¹°À» Á¤È®ÇÏ°Ô Á¤·®ÇÒ ¼ö ÀÖ¾î Ä¡·á ¸ð´ÏÅ͸µÀÇ ÃֽŠ¿ä±¸»çÇ×À» ÃæÁ·½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç÷¾×À» ÀÌ¿ëÇÑ TDMÀ» ÁöÁöÇÏ´Â ±ÔÁ¦ °¡À̵å¶óÀΰú ÀÓ»ó °üÇà¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¿ë·® ÃÖÀûÈ­¸¦ À§ÇÑ ¾àµ¿ÇÐ ¸ð´ÏÅ͸µ¿¡¼­ ±× ÀÌÁ¡ÀÌ ÀÔÁõµÇ¾î Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ ÀÓ»ó ÇöÀå¿¡¼­ÀÇ Ã¤Åÿ¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

"¹Ì±¹ÀÌ ºÏ¹Ì ¾à¹° ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀÔ´Ï´Ù."

¹Ì±¹¿¡¼­´Â ½ÉÇ÷°üÁúȯ, ´ç´¢º´, ½Å°æ Áúȯ, ¾Ï°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 TDM¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ Áß ÀϺδ ºÎÀÛ¿ëÀ» ÁÙÀ̱â À§ÇÑ Á¶Ä¡¸¦ ÃëÇÏ¿© Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇØ Ã¶ÀúÇÑ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ TDM ±â¼ú äÅà ¼Óµµ°¡ »¡¶óÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áß±¹ÀÇ ÀÇ·á ü°è°¡ Àß ±¸ÃàµÇ¾î ÀÖ°í, ¸¹Àº º´¿ø, ¿¬±¸¼Ò, Áø´Ü ¼¾ÅͰ¡ Á¸ÀçÇϱ⠶§¹®¿¡ ¼±ÁøÀûÀÎ ¿£µå-Åõ-¿£µå ÅëÇÕÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¸¹Àº Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ Á¸Àç·Î µÞ¹ÞħµÇ´Â TDM ±â¼úÀÇ ²÷ÀÓ¾ø´Â Çõ½ÅÀº ¸ð´ÏÅ͸µ µµ±¸ÀÇ °¡¿ë¼º°ú Áøº¸¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç ¿äÀεéÀÌ °áÇÕµÇ¾î ¹Ì±¹ TDM ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ÁÖ¿ä ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ, °æÀï »óȲ, ÇâÈÄ µ¿Çâ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : Á¦Ç°º°

Á¦7Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : ±â¼úº°

Á¦8Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : ¾à¹° Á¾·ùº°

Á¦9Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : Ä¡·á ºÐ¾ßº°

Á¦10Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : °Ëüº°

Á¦11Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå Ä¡·áÁ¦ ¸ð´ÏÅ͸µ(TDM) ½ÃÀå : Áö¿ªº°

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

It is anticipated that the therapeutic drug monitoring market will grow from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, with a steady compound annual growth rate (CAGR) of 8.4%. Advancements in immunoassay techniques remain a key driver of this growth, influencing the sector's trajectory in a positive manner. These techniques aim to improve the accuracy, speed, and specificity of medication monitoring, including enhanced chemiluminescence, ELISA, and fluorescence enhancement. In the meantime, healthcare professionals are becoming more aware of the significance of TDM in improving therapeutic outcomes, leading to its incorporation into clinical settings. Education and training initiatives have raised clinicians' understanding of the advantages of TDM, making it easier for the technology to be implemented in everyday patient care. Collaboratively, these elements are influencing a dynamic and growing market environment.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Product, Technology, Drug Class, Therapeutic Area, Specimen, End User, and Region
Regions coveredNorth America, Europe, APAC, Latin America, Middle East & Africa, and GCC Countries.

"Consumables segment is expected to grow at the highest CAGR during the forecast period, by product."

The consumables segment holds the highest CAGR in the therapeutic drug monitoring. Consumables such as reagents, assay kits, and calibrators create a very important part in the TDM market as they are integral in routine monitoring of drugs for chronic but complex-to-cure conditions such as cancer, cardiovascular, and neurological disorders. Demand for high-quality consumables is growing as a result of the increased focus on customized therapy and the need for precise medication level evaluation. Additionally, spending money on advanced TDM systems produced by labs and hospitals would raise demand for its related goods, which would support market expansion.

"Blood segment is expected to hold the largest share of TDM market during the forecast period, by specimen."

Blood, as it is the most used specimen for TDM, fuels the market owing to its capability to provide precise and direct measurement of drug concentrations in plasma or serum. Well-established protocols in the collection and processing of blood ensure that it is reliable and consistent, while its wide clinical acceptance is well established. It is compatible with the most advanced technologies, including immunoassays and LC-MS/MS, by which drugs can be accurately quantified, meeting modern demands in therapeutic monitoring. Besides, this is supported by regulatory guidelines and clinical practices, which favor blood-based TDM; it has proved its merit in monitoring pharmacokinetics for the optimization of dose , which improves therapeutic outcomes, all combining to favor its adoption in a clinical setting.

"US to grow at the highest CAGR for North America therapeutic drug monitoring market"

The increasing prevalence in the US of chronic diseases of a cardiovascular nature, diabetes, neurological disorders, and cancer, among many others, significantly fuels this demand for TDM. Several of these disorders require thorough monitoring for the optimization of their treatment efficacy by taking measures to reduce adverse events, hence increasing the pace of adoption of TDM technologies. The well-established and well-developed healthcare framework of the country involves large numbers of hospitals, laboratories, and diagnostic centers, which further fortifies the integration of advanced end. Besides, continuous innovation in TDM technologies, supported by the presence of numerous pharmaceutical and biotech companies, ensures availability and advances in monitoring tools. These are all factors combined to spur the rapid growth of the TDM market in the US.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the therapeutic drug monitoringmarketplace.

The companies included in Therapeutic Drug Monitoring market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK), apDia Group (Belgium), BBI Solutions (UK), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), UTAK (US), Sekisui Medical Co., Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), BUHLMANN Laboratories AG (Switzerland), SJK Global, LLC (US), Epitope Diagnostics, Inc. (US), QED Bioscience Inc. (US), Boditech Med Inc. (South Korea), and Immunodiagnostic Systems (UK).

Research Coverage

This research report categorizes the therapeutic drug monitoring market by product (Equipment, and Consumables), by technology (Immunoassays, Chromatography-MS, and Other Technologies), by Drug Class (Anti-Epileptic Drugs, Anti-Arrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Bronchodilator Drugs, Psychoactive Drugs, and Other Drug Classes), by Therapeutic Area (Neurological Disorders , Cardiology, Infectious Diseases, Oncology, Other Therapeutic Areas), by Specimen (Blood, Saliva, and other samples), by End User (Hospital Laboratories, Commercial & Private Laboratories, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Gountries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the therapeutic drug monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the therapeutic drug monitoring market. Competitive analysis of upcoming startups in the therapeutic drug monitoring market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall therapeutic drug monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA

10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN

11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES

15 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â